Concourse Financial Group Securities’s BioCryst Pharmaceuticals BCRX Stock Holding History

Concourse Financial Group Securities’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,300	Closed	-$7.17K	–	2300
2024 Q1	$6.6K	Hold	1,300	–	–	﹤0.01%	1831
2023 Q4	$7.79K	Hold	1,300	–	–	﹤0.01%	1748
2023 Q3	$9.2K	Sell	1,300 -1	-0.1%	-$7	﹤0.01%	1670
2023 Q2	$9.16K	Hold	1,301	–	–	﹤0.01%	1673
2023 Q1	$10.8K	Buy	1,301 +1	+0.1%	+$10	﹤0.01%	1648
2022 Q4	$14.9K	Hold	1,300	–	–	﹤0.01%	1550
2022 Q3	$16K	Hold	1,300	–	–	﹤0.01%	1358
2022 Q2	$14K	Hold	1,300	–	–	﹤0.01%	1551
2022 Q1	$21K	Buy	1,300 +500	+63%	+$8.02K	﹤0.01%	1463
2021 Q4	$11K	Hold	800	–	–	﹤0.01%	1831
2021 Q3	$11K	Hold	800	–	–	﹤0.01%	1854
2021 Q2	$13K	Hold	800	–	–	﹤0.01%	1775
2021 Q1	$8K	Hold	800	–	–	﹤0.01%	1812
2020 Q4	$6K	Hold	800	–	–	﹤0.01%	1830
2020 Q3	$3K	Buy	+800	New	+$3.43K	﹤0.01%	1918

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Concourse Financial Group Securities's BCRX Position: Q2 2024 in Review

Concourse Financial Group Securities sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 1,300 shares — an estimated $7.17K sold.

Concourse Financial Group Securities first reported a position in BCRX in Q3 2020 and held it in 15 quarters. The position peaked at $21K in Q1 2022. 242 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

Concourse Financial Group Securities reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Concourse Financial Group Securities sold 1,300 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $7.17K.
Concourse Financial Group Securities first reported a position in BioCryst Pharmaceuticals in Q3 2020 and held it in 15 quarters.
Concourse Financial Group Securities's BioCryst Pharmaceuticals position peaked at $21K in Q1 2022.
242 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on Concourse Financial Group Securities's 13F filing for Q2 2024, filed 23 Jul 2024.